[go: up one dir, main page]

TNSN99132A1 - Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause - Google Patents

Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause

Info

Publication number
TNSN99132A1
TNSN99132A1 TNTNSN99132A TNSN99132A TNSN99132A1 TN SN99132 A1 TNSN99132 A1 TN SN99132A1 TN TNSN99132 A TNTNSN99132 A TN TNSN99132A TN SN99132 A TNSN99132 A TN SN99132A TN SN99132 A1 TNSN99132 A1 TN SN99132A1
Authority
TN
Tunisia
Prior art keywords
osteoporosis
prevention
composition
treatment
menopause syndrome
Prior art date
Application number
TNTNSN99132A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of TNSN99132A1 publication Critical patent/TNSN99132A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

-UNE COMPOSITION QUI PEUT PRENDRE LA FORME D'UN SUPPLEMENT DIETETIQUE OU D'UN MEDICAMENT EFFECTIF EST DIVULGUEE PAR CETTE INVENTION ET COMPREND COMME INGREDIENTS ACTIFS ET CARACTERISTIQUES LE PROPIONYL L- CARNITINE ET L'ISOFLAVONE (FGENISTEIN), DESTINEE A LA PREVENTION ET/OU AU TRAITEMENT THERAPEUTIQUE DE L'OSTEOPOROSE ET DU SYNDROME DE MENOPAUSE
TNTNSN99132A 1998-06-23 1999-06-23 Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause TNSN99132A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000417A IT1299191B1 (it) 1998-06-23 1998-06-23 Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa

Publications (1)

Publication Number Publication Date
TNSN99132A1 true TNSN99132A1 (fr) 2005-11-10

Family

ID=11406005

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99132A TNSN99132A1 (fr) 1998-06-23 1999-06-23 Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause

Country Status (27)

Country Link
US (1) US6335038B1 (fr)
EP (1) EP1089742B1 (fr)
JP (1) JP4430233B2 (fr)
KR (1) KR20010071541A (fr)
CN (1) CN1306434A (fr)
AR (1) AR018924A1 (fr)
AT (1) ATE228367T1 (fr)
AU (1) AU755272B2 (fr)
BR (1) BR9911440A (fr)
CA (1) CA2334875C (fr)
DE (1) DE69904172T2 (fr)
DK (1) DK1089742T3 (fr)
EE (1) EE200000741A (fr)
ES (1) ES2188177T3 (fr)
HU (1) HU224957B1 (fr)
IL (1) IL140163A0 (fr)
IS (1) IS5764A (fr)
IT (1) IT1299191B1 (fr)
MA (1) MA26655A1 (fr)
NO (1) NO20006431L (fr)
NZ (1) NZ508877A (fr)
PL (1) PL192118B1 (fr)
PT (1) PT1089742E (fr)
SK (1) SK19292000A3 (fr)
TN (1) TNSN99132A1 (fr)
TR (1) TR200003735T2 (fr)
WO (1) WO1999066913A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302863B1 (it) * 1998-11-13 2000-10-10 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un
US6476010B2 (en) * 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
US20010039296A1 (en) * 2000-03-23 2001-11-08 Debasis Bagchi Method and composition for preventing or reducing the symptoms of menopause
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
IT1317079B1 (it) 2000-12-21 2003-05-26 Sigma Tau Ind Farmaceuti Uso della isovaleril l-carnitina per la preparazione di un medicamentoper la prevenzione e cura dell'osteoporosi.
EP1372412A2 (fr) * 2001-03-09 2004-01-02 Societe Des Produits Nestle S.A. Preparation attenuant les deficits physiologiques lies a l'age et augmentant la longevite
ES2289097T3 (es) * 2001-03-15 2008-02-01 Dsm Ip Assets B.V. Composicion para la prevencion de la osteoporosis consistente de una combinacion de isoflavonas y acidos grasos poliinsaturados.
AUPR957001A0 (en) * 2001-12-19 2002-01-24 Novogen Research Pty Ltd Isoflavone conjugates, derivatives thereof and therapeutic methods involving same
JP2005524638A (ja) * 2002-02-15 2005-08-18 エヌ・ヴイ・ヌートリシア 骨粗しょう症及び肥満処置用医薬の製造におけるゲニステインの使用及びビタミンｄ及びｋと組合わせてゲニステインを含有する組成物
KR100542478B1 (ko) * 2002-08-28 2006-01-11 한경대학교 산학협력단 석류 유래 피토에스트로겐을 함유하는 건강기능식품
CN1681484B (zh) * 2002-09-09 2012-06-06 雀巢技术公司 用于改善皮肤质量的口服施用组合物
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
EP2218342B1 (fr) * 2003-05-27 2018-07-04 DSM IP Assets B.V. Nouvelles compositions nutraceutiques et utilisations
JP2005187454A (ja) * 2003-12-05 2005-07-14 Sankyo Co Ltd ビタミンｅ含有ｌｄｌ低下剤及び／又は動脈硬化抑制剤組成物
BRPI0507253A (pt) * 2004-01-28 2007-06-26 Nestec Sa composição nutricional para melhorar as condições da pele e prevenir doenças de pele
CN1842327B (zh) * 2004-02-03 2011-05-11 株式会社红豆杉 将源于云南红豆杉的异紫杉脂素作为成分的骨质疏松症预防、治疗药
ES2346234T3 (es) * 2004-03-17 2010-10-13 Nestec S.A. Composiciones y metodos para reducir o evitar la obesidad.
CN100351248C (zh) * 2004-07-05 2007-11-28 南京大学 染料木素衍生物及其制法和用途
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
DE102004060314A1 (de) * 2004-12-08 2006-08-31 Beiersdorf Ag Wirkstoffkombinationen aus einem oder mehreren Isoflavonoiden und Carnitin und/oder einem oder mehreren Acyl-Carnitinen
DK1830883T3 (da) 2004-12-29 2013-11-25 Hills Pet Nutrition Inc Fremgangsmåde til at hæmme en nedgang i indlæring og/eller hukommelse hos dyr
JP2008526819A (ja) * 2005-01-10 2008-07-24 ホルモス メディカル リミテッド エストロゲン欠乏に関連する症状を予防または改善するための組成物を製造するためのリグナンの使用
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
JP5112308B2 (ja) * 2005-07-08 2013-01-09 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 角膜疾患の治療のための食餌サプリメントまたは医薬の調製のためのｌ−カルニチンまたはアルカノイルｌ−カルニチン、脂溶性ベンゾキノンおよびオメガ−３−多価不飽和脂肪酸を含む組合せの使用
AU2006267068B2 (en) 2005-07-14 2011-01-06 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
JP2009511523A (ja) * 2005-10-14 2009-03-19 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロールを含むニュートラシューティカル組成物の新規な使用
BRPI0618222A2 (pt) * 2005-11-02 2011-08-23 Nestec Sa composições de isoflavona para reduzir o acúmulo de gordura corporal em animais machos, e métodos para seu uso
US20090221690A1 (en) * 2006-02-28 2009-09-03 Council Of Scientific And Industrial Research Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof
BRPI0708361A2 (pt) 2006-02-28 2011-05-24 Nestec Sa composições e métodos para a indução de crescimento ósseo e para a inibição de perda óssea
PL2189155T3 (pl) * 2006-04-12 2016-07-29 Unilever Nv Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
US8987329B2 (en) * 2006-04-12 2015-03-24 Conopco, Inc. Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
WO2007116052A1 (fr) * 2006-04-12 2007-10-18 Unilever Plc Composition orale à dha/génistéine pour ameliorer des proprietes de la peau
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
RU2509768C2 (ru) 2008-09-10 2014-03-20 Асахи Гласс Компани, Лимитед Новое производное простагландина i2
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
EP2344153A1 (fr) * 2008-11-11 2011-07-20 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composé utile pour le traitement de la cellulite
KR101158856B1 (ko) 2009-05-12 2012-06-25 한국생명공학연구원 콩잎 추출물 또는 이의 분획물을 유효성분으로 함유하는 비만, 고지혈증, 동맥경화, 지방간, 당뇨 또는 대사증후군의 예방 또는 치료용 조성물
ES2593229T3 (es) * 2010-03-08 2016-12-07 Kaken Pharmaceutical Co., Ltd. Nuevo agonista de EP4
KR20130089158A (ko) * 2010-06-16 2013-08-09 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 신경 조직에서 신경발생을 증가시키기 위한 방법에 사용하기 위한 아세틸-카르니틴
WO2012011572A1 (fr) * 2010-07-23 2012-01-26 国立大学法人大阪大学 Agent thérapeutique pour insuffisance cardiaque diastolique
IT201700116392A1 (it) * 2018-04-03 2019-10-03 Composizione per somministrazione orale aventi benefico effetto sulla salute della donna in menopausa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases

Also Published As

Publication number Publication date
JP4430233B2 (ja) 2010-03-10
PL345030A1 (en) 2001-11-19
AU755272B2 (en) 2002-12-05
IT1299191B1 (it) 2000-02-29
HUP0102879A2 (hu) 2002-03-28
DE69904172D1 (de) 2003-01-09
DK1089742T3 (da) 2003-03-24
CA2334875C (fr) 2009-05-12
ITRM980417A1 (it) 1999-12-23
NO20006431L (no) 2001-02-22
NO20006431D0 (no) 2000-12-15
HUP0102879A3 (en) 2002-12-28
NZ508877A (en) 2002-09-27
BR9911440A (pt) 2001-03-20
MA26655A1 (fr) 2004-12-20
PT1089742E (pt) 2003-04-30
SK19292000A3 (sk) 2001-08-06
IL140163A0 (en) 2002-02-10
JP2002518437A (ja) 2002-06-25
PL192118B1 (pl) 2006-09-29
ITRM980417A0 (it) 1998-06-23
ES2188177T3 (es) 2003-06-16
WO1999066913A3 (fr) 2000-04-20
EP1089742A2 (fr) 2001-04-11
KR20010071541A (ko) 2001-07-28
AU4390999A (en) 2000-01-10
EE200000741A (et) 2002-04-15
CA2334875A1 (fr) 1999-12-29
IS5764A (is) 2000-12-08
CN1306434A (zh) 2001-08-01
WO1999066913A2 (fr) 1999-12-29
DE69904172T2 (de) 2003-08-28
US6335038B1 (en) 2002-01-01
AR018924A1 (es) 2001-12-12
EP1089742B1 (fr) 2002-11-27
ATE228367T1 (de) 2002-12-15
TR200003735T2 (tr) 2001-03-21
HU224957B1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN99163A1 (fr) COMPOSITION ANTIOXYDANTE COMPRENANT L'ACETYL-CARNITINE ET L'ACIDE α -LIPOIQUE QUI AMELIORE L'UTILISATION METABOLIQUE DU GLUCOSE
TNSN99135A1 (fr) Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
CA2339221A1 (fr) Extraits de chrysanteme-matricaire (tanacetum parthenium) utilises contre les troubles inflammatoires
BR0008059A (pt) Composições de valdecoxib
BG104727A (en) Pharmaceutical composition of topiramate
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
LV12766A (lv) Composition of l-dopa esters
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
IL139320A0 (en) Pharmaceutical compositions containing human parathyroid hormone
ES2128051T3 (es) Isomero de doble enlace de la equilina, procedente de la isomerizacion acida de la equilina.
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
TNSN00186A1 (fr) Une composition pour la prevention et/ou le traitement des troubles circulatoires comportant des derives de l-carnitine et des extraits de ginkgo biloba
TNSN00083A1 (fr) Une composition contenant un carnitine et un phosphate d'inositol utilisee comme supplement dietetique ou medicament
TNSN01076A1 (fr) Associations de secretagogues d'hormone de croissance et d'antidepresseurs, et compositions les contenant
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CA2226140A1 (fr) Composes pour traiter ou prevenir l'osteosporose et les symptomes associes avec la menopause
TNSN99212A1 (fr) Composition antioxydante et preventive contre les anomalies thrombotiques et atherosclerotiques, comportant un carnitine et un flavonoide
FR2374044A1 (fr) Agent anti-diabetique oral contenant une sulfonyluree et une kinine
DE60215812D1 (de) Orale zusammensetzungen zur behandlung von adipösen, nicht diabetischen säugetieren, einschliesslich menschen
KR960000248A (ko) 골대사 질환 치료제